Article
Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma.
European journal of cancer (Oxford, England : 1990) - 1 Jan 2018
Lowery Maeve A, Kelsen David P, Capanu Marinela, Smith Sloane C, Lee Jonathan W, Stadler Zsofia K, Moore Malcolm J, Kindler Hedy L, Golan Talia, Segal Amiel, Maynard Hannah, Hollywood Ellen, Moynahan MaryEllen, Salo-Mullen Erin E, Do Richard Kinh Gian, Chen Alice P, Yu Kenneth H, Tang Laura H, O'Reilly Eileen M
Abstract excerpt
PURPOSE: BRCA-associated cancers have increased sensitivity to poly(ADP-ribose) polymerase inhibitors (PARPis). This single arm, non-randomised, multicentre phase II trial evaluated the response rate of veliparib in patients with previously treated BRCA1/2- or PALB2-mutant pancreatic adenocarcinoma (PDAC). METHODS: Patients with stage III/IV PDAC and known germline BRCA1/2 or PALB2 mutation, 1-2 lines of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.